Background: Our objective was to determine the variability in assessment between investigators (INV) and independent review committees (IRC) for response rate (RR) and progression-free survival (PFS).
introduction
Advances in cancer therapy are built upon successive randomized, phase III clinical trials. In these studies, new agents or combinations are compared with the commonly accepted standard of care at the time, and statistically significant differences in favor of new strategies often lead to the acceptance of new standards of care and the approval of new agents by regulatory agencies. While overall survival is the traditional end point in these studies, end points on the basis of tumor responses, such as response rate (RR) and progression-free survival (PFS), are increasingly employed and accepted as surrogates, particularly when molecular targeted agents are evaluated [1] . For solid malignancies, RR is on the basis of a reduction in sizes of tumor lesions assessed clinically or radiologically, while PFS is commonly defined as the time from randomization to disease progression or death from any cause. Therefore, determination of RR and PFS depends on accurate assessment of changes in sizes of tumor lesions. Although standardized criteria, such as World Health Organization (WHO) and RECIST, have been developed to improve the evaluation and reporting of objective tumor outcomes [2] [3] [4] , the prerequisite of these criteria is still an accurate and unbiased determination of sizes of tumor lesions.
It has been reported that assessment of tumor lesions is subject to both inter-and intraobserver variability [5] [6] [7] [8] [9] . Recognizing these limitations, both RECIST and WHO recommend the use of independent review committees (IRC) to ensure consistency and minimize bias in all clinical trials, especially if the primary end point is on the basis of tumor response [2] [3] [4] . Not surprisingly, IRC-determined end points have been reported to differ from those determined by investigators (INV). In the phase II setting, INV-determined RR (RR INV ) is often higher than that obtained by IRC (RR IRC ) [10] [11] [12] . Similarly, the estimation of PFS can differ between INV and IRC as well. Hecht et al. [13] conducted a phase III study in which patients with untreated metastatic colorectal cancer were randomized to FOLFOX and PTK787 or FOLFOX alone. The primary end point of this study was PFS as determined by IRC. The addition of PTK787 significantly improved PFS as assessed by INV (PTK787 7.7 months versus placebo 7.5 months, HR = 0.83, P = 0.026) but did not on the basis of assessment by IRC (7.7 versus 7.6 months, HR = 0.88, P = 0.118). As a result, the development of PTK787 was abandoned.
Although the potential impact on the outcome of a clinical trial and the continuing development of new agents is large, the disparity between INV and IRC assessments on tumor responses has not been systemically evaluated. We undertook this study to determine the variability in assessment between INV and IRC for RR and PFS.
methods
Randomized phase III clinical trials evaluating systemic therapy published from January 1995 to January 2007 were identified through a systematic search of Medline using the keyword 'neoplasm metastasis'. Results were limited to 'clinical trial' or 'clinical trial, phase III' or 'controlled clinical trial' or 'randomized controlled trial'. In addition, a manual search was carried out for abstracts presented at the annual meetings of the American Society of Clinical Oncology from 2004 to 2007 for unpublished studies. Exclusion criteria included studies with <100 patients per study arm or those involving pediatric population (<18 years of age), supportive care, palliative care, hematological malignancies, and prevention. Trials that reported assessments of RR or PFS by both INV and IRC were selected for analysis.
data collection
For each trial, we collected the following information: year of publication, journal of publication, cancer type, type of therapy, number of patients, number of treatment arms, criteria used to assess response (WHO or RECIST), primary end point, RR, and PFS (INV and IRC determined). If both per protocol and intent-to-treat (ITT) results were available, only ITT data were included in the analysis. Information regarding prevalence and explanations for discordance between INV and IRC assessments was also recorded.
statistical analysis
Descriptive statistics were used to summarize the trial characteristics, as well as RR and PFS observed across experimental and control study arms separately and together. Response was defined as a partial or complete response according to the criteria used by the trial (WHO or RECIST). The difference in RR assessment (DRR IRC2INV ) in the same study arm was defined as RR IRC 2 RR INV . Similar calculations were carried out for the difference in median PFS. Regression methods were used with a randomeffects model to calculate the mean difference between RR INV and RR IRC across all study arms. Results were similar if a weight function was added or if no adjustment for potential correlation was carried out; hence, only results from the random-effects model are reported.
To explore whether there was a systemic bias in favor of the experimental arm compared with the control arm in a study by INV, the estimated benefit of the experimental arm was calculated for IRC and INV assessments separately. That is, assuming that the true benefit of the experimental arm over the control arm in a study is D IRC (RR exp [14] . Thus, 21 trials were included in this analysis: 18 reported RR and 8 reported median PFS [13, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . Three trials were placebo controlled [13, 29, 33] . Characteristics of the trials are summarized in Tables 1  and 2 . The median sample size was 462 (range 200-2034). The NO16966 trial was amended part way through its conduct to incorporate a 2 · 2 factorial design and was reported twice in abstract form [27, 35] . Due to the overlap in patients, only data from the larger analysis were used [27] . One trial included cancer-specific mortality in the definition of time to progression and was labeled PFS in this analysis [26] . The trial by Tournigand et al. [23] randomized patients with metastatic colorectal cancer to 5-fluorouracil, leucovorin, irinotecan followed by FOLFOX or the reverse sequence. Only data from the first randomization were used in this analysis as sample sizes after the second randomization did not meet the predefined criteria (>100 patients per treatment arm). One trial reported RR INV and RR IRC assessed at different points in time; this study was not included in the RR analysis [29] . One trial provided RR INV and RR IRC data and stated that there was no statistically significant difference in PFS between the experimental and control arms for PFS but did not provide a magnitude for median PFS or a hazard ratio (HR) [25] . This study was included in the analysis of RR but only for concordance for PFS. PFS was defined in one trial as a composite end point of radiological progression, symptomatic progression, skeletal events, or death [33] .
frequency of disagreement between IRC and INV within trials
Only two trials provided information regarding frequency of disagreement between IRC and INV [25, 26] . The rate of discordance between INV and IRC on disease progression was 22.7% and 25%, respectively. Reasons for discordance included alternative interpretation of lesions, selection of different lesions [26] , and determination of progression on the basis of physical exams by INV which could not be confirmed by IRC [25] . The trial by Sternberg et al. [33] mandated response review by two independent radiologists. Of 950 patients enrolled, adjudication was required to determine disease progression in 336 patients (35%) [36] .
difference between IRC-and INV-determined end points RR IRC is plotted against RR INV from the same study arm in Figure 1 . Although the magnitudes of DRR IRC2INV are often different between study arms in the same trial, the directionality (over or underestimation) was consistent in 15 of 18 trials (83.3%). There were three instances (experimental and control arms of Miller et al. [25] and the control arm of Cassidy et al. [27] ), in which RR INV differed from RR IRC by ‡10%. In all three cases, RR INV was higher than RR IRC .
The estimated mean difference in PFS using a random-effects model was ‡0.19 (95% CI 20.68 -+0.29) months.
There was over-and underestimation of benefits for the experimental arm compared with the control arm in terms of RR and PFS (Figure 2) . Overall, the difference in estimated RR benefits (RR exp 2 RR con ) between INV and IRC was low (mean = 20.2, median = 21.0), and there was no evidence of a systemic bias by INV (P = 0.54). However, there were wide variations (range 27.0% to +7.2%) between trials. In one extreme example, the estimated benefit by INV (RR exp 2 RR con ) was 0, while that assessed by IRC was 27% [28] . The concordance/discordance of study conclusions on the basis of IRC and INV assessment is shown in Table 2 . In 2 of the 18 trials reporting RR, a statistically significant difference was concluded by INV but not by IRC [21, 26] . In one of the nine trials that reported PFS, there was a significant difference by INV assessment but not on the basis of IRC assessment. All trials reporting statistical significance on the basis of IRC assessment also reached the same conclusion on the basis of INV assessment. Four trials reported HRs for PFS by IRC and INV (Table 3) . Two trials reported similar HR for INV and IRC [13, 31] , and two trials had differences of ‡0.09 [26, 33] .
discussion
Our literature-based analysis reveals that INV differ from IRC in assessing tumor outcomes in randomized phase III studies and is the largest review to date on this topic. INV tend to overestimate RR compared with IRC, and the INV-determined RR was, on average, 4.57% (95% CI 2.95% to 6.19%) higher than that determined by IRC. However, there was no evidence of a systemic bias. Results from this study are consistent with findings in the phase II setting [10] [11] [12] . Ford et al. [37] also found that the INV-assessed RR was consistently higher than the IRC in seven phase III trials reported in the medical literature and discussed at USA Food and Drug Administration (FDA) Oncology Drugs Advisor Committee meetings.
Although RR was the basis of approval for 26 of 57 oncology drugs by the USA FDA from 1990 to 2002 [1] , it is seldom used as the primary end point in modern phase III trials. PFS, also on the basis of assessment of changes in tumor lesions, was the primary end point in many recent phase III trials [38] [39] [40] . The USA FDA has accepted PFS as the primary end point in registration trials. There was no significant difference between IRC-and INV-determined median PFS (0.19 months, 95% CI 20.68 to +0.29 months). However, there was substantial variability between IRC-and INV-assessed median PFS as well as estimation of PFS benefit. Patient-level discordance rates regarding progression status between IRC and INV range from 24% to 29% [25, 26, 36, 41] . In the study by Sternberg et al. [36] , the two independent radiologists that reviewed images required adjudication to determine progression in 35% of cases, highlighting the difficulty in assessing progression. It is important to note that not all advances in cancer therapy result in large improvements in median PFS. For example, panitumumab was approved for the treatment refractory metastatic colorectal cancer in the United States on the basis of improved PFS of <1 week (median PFS: 8 weeks for panitumumab versus 7.3 weeks for best supportive care, HR = 0.54; 95% CI 0.44 to 0.66, P < 0.0001) [42] . These small improvements could easily be masked by variabilities in assessments. Furthermore, small differences in PFS can lead to opposite study conclusions, as illustrated by the trial reported by Hecht et al. [13] . Finally, the cost of new cancer treatments is increasing exponentially. Thus, estimations of PFS could potentially have a large impact on decisions regarding drug funding. In our study, information regarding the timing of radiological assessment was available for seven of the eight trials. Per protocol evaluations occurred at the same time interval for all treatment arms, at least every 6-8 weeks; thus, it is likely that the timing of PFS assessment did not affect the comparison.
There are many possible reasons for discrepancies between IRC and INV assessments in tumor outcomes [37] . First, RR Hecht et al. [13] 0.88 (0.74-1.03; P = 0.118) 0.83; P = 0.026 Geyer et al. [26] 0.49 (0.34-0.71; P < 0.001) 0.59 (0.42-0.84; P = 0.002) Motzer et al. [31] 0.42 (0.32-0.54; P < 0.001) 0.42 (0.33-0.52; P < 0.001) Sternberg et al. [33] 0.67 (0.57-0.77; P < 0.0000003) 0.58 (0.50-0.67; P < 0.000000000002) PFS, progression-free survival; IRC, independent review committee. and PFS are estimates, and some variability is expected due to chance alone. Secondly, INV often lack formal training in radiology and may not able to detect subtle appearance of new lesions or reliably determine changes in sizes of tumor lesions over time especially if the tumor response was assessed by multiple INV over time. Variations in lesion selection can also account for discrepancies [43] . Lastly, INV can be influenced by knowledge of the clinical status of a patient, resulting in assessment bias. This occurs when an INV labels a borderline case stable disease if the patient is doing well clinically but would not do so if the patient is deteriorating clinically. Alternatively, this can result in informative censoring, when a patient is deteriorating clinically but is objectively considered as having stable disease as described by Dodd et al. [44] . These patients are more likely to progress objectively shortly after treatment is stopped (i.e. patient is censored) than a patient who is lost to follow-up, withdraws, or is removed due to toxicity. Informative censoring can be minimized by real-time IRC progression assessments, mandating follow-up imaging after INV-assessed progression until IRC confirmation, or the use of blinding [45] . However, it cannot be entirely eliminated. Thus, whenever IRC methods are used, a detailed definition of PFS is essential [46] and standardization of definitions across studies would be useful. The literature-based nature of this study presents some limitations. We are surprised that only a small proportion of randomized phase III trials reported both IRC and INV assessments, especially with respect to PFS. Frequency of disagreement between IRC and INV and reasons for discrepancies were not consistently described. Thus, these factors could not be explored in this analysis. PFS was also defined differently between studies; thus, it is possible that this may have masked a bias. However, it is believed unlikely that different definitions give substantially different estimates of objective PFS in large studies and unlikely that the different definitions would promote a systematic bias.
In our analysis, it is evident that there is considerably variability in assessing RR and PFS between INV and the IRC. This variability could potentially change the conclusion of a trial, from statistically nonsignificant to statistically significant or vice versa. Thus, an IRC should be considered in every randomized phase III trial in oncology if the primary end point is on the basis of tumor response or progression. Furthermore, this variability should be taken into consideration in sample size calculation and interim analysis. An IRC should also be incorporated prospectively if new end points, such as time to failure of treatment strategy, are explored [47] . Lastly, both INV and IRC assessments should be reported. 
